What Xalacom treats: main uses and benefits

Xalacom is a fixed-combination ophthalmic solution used for the management of elevated pressure within the eye. Its primary therapeutic use is the reduction of intraocular pressure (IOP), which is a common requirement in conditions presenting with acute episodes of elevated pressure.

The product is used for managing eye pressure in patients with open-angle glaucoma and ocular hypertension. These are conditions where functional stability can be affected and can involve symptoms that create noticeable physiological strain.

The solution combines two active components. This combination assists with maintaining functional stability and contributes to easing the overall symptom load associated with heightened physiological activity. This product is used in situations where additional symptomatic support is needed to control pressure effectively.

The combination assists with maintaining functional stability and supports physiological balance during symptomatic phases.

Quick Fact: Supports physiological stability during symptomatic phases.

Who Can and Cannot Use Ксалаком?

The population eligibility for Ксалаком (Latanoprost/Timolol) is strictly defined by regulatory guidelines, primarily focusing on absolute prohibitions (contraindications) and age restrictions.

---

Populations Who Must Not Use (Contraindicated)

Use is absolutely contraindicated in patients with known hypersensitivity to Latanoprost, Timolol, or any excipient. Due to the Timolol (beta-blocker) component, the medicine is also prohibited in patients with serious cardiorespiratory conditions, including bronchial asthma, a history of asthma, severe Chronic Obstructive Pulmonary Disease (COPD), sinus bradycardia, overt cardiac failure, or second/third-degree AV block.

---

Eligibility and Restrictions

Category	Regulatory Status
Adults and Elderly	Eligible for use, with no dose adjustment required for the elderly.
Children and Adolescents	Not recommended for those under 18 years of age, as safety and efficacy have not been established.
Pregnancy	Not recommended; use only if clearly necessary.
Breastfeeding	Contraindicated, as the active ingredients are excreted in breast milk.
Organ Impairment	Use is advised with caution in patients with hepatic or renal impairment due to limited clinical experience.

Interactions with other medicines and products

The interaction profile for Ксалаком (Latanoprost/Timolol) is determined by the presence of both a prostaglandin analogue and a non-selective beta-blocker. Interaction-related restrictions mandate that co-administration with other topical prostaglandin analogues or two or more topical beta-adrenergic blocking agents is not recommended due to the risk of paradoxical effects or compounded systemic beta-blockade.

Pharmacodynamic and Metabolic Interactions

Interacting Substance/Class	Official Interaction Description
Systemic Beta-blockers or Calcium Channel Blockers	Potential for additive effects resulting in hypotension or marked bradycardia (slowed heart rate).
CYP2D6 Inhibitors (e.g., Quinidine)	May lead to potentiated systemic beta-blockade due to increased Timolol exposure.
Antidiabetic Agents (e.g., Insulin)	Beta-blockers may increase the hypoglycaemic effect and mask the signs of acute hypoglycemia.

Administration Timing Constraints

If co-administered with any other topical ophthalmic drug products, the medications must be administered at least five (5) minutes apart to prevent chemical incompatibility or dilution. This rule is crucial for products containing Thimerosal, which can cause precipitation when combined with latanoprost.

Population-Specific Notes

A specific caution is officially noted for patients with diabetes receiving antidiabetic treatment, as the beta-blocker component may mask the signs of a low blood sugar episode. Anaesthesiologists must also be informed of Timolol use before surgery.

How Ксалаком Works: Mechanism of Action

Ксалаком is a fixed-combination agent whose pharmacodynamic activity results from two distinct mechanisms influencing the eye's fluid dynamics. The first component acts as an agonist on specific PGF2alpha receptors located on cells within the uveoscleral tract of the eye. This interaction modifies the structural integrity of the tissue, initiating a cascade that increases the physical outflow of aqueous humor from the anterior chamber.

The second component acts as a non-selective beta-adrenergic receptor blocker on the ciliary body epithelium. This inhibitory action dampens the signaling cascade, including the cAMP pathway, required for the active secretion of aqueous humor. This effectively decreases the rate at which new fluid is formed. The synergistic combination of enhanced fluid exit and reduced fluid creation leads to a comprehensive net decrease in the total volume of fluid contained within the eyeball, producing a measurable alteration in the internal hydrostatic pressure.

How to Use Ксалаком: Administration Guidelines

Ксалаком (Latanoprost/Timolol) is a prescription ophthalmic solution whose administration follows specific protocols to ensure consistent use and efficacy.

Standard Dosing and Frequency

The medicine is administered via the topical ophthalmic route only. The standard adult dose is one drop instilled into the affected eye(s). This single drop represents the maximum daily dose and should not be exceeded, as more frequent administration may reduce the medication's intended effect. The drug is taken once daily, with administration often suggested in the evening, which aligns with the established profile of the latanoprost component.

Procedural and Population Constraints

Constraint Area	General Procedural Instructions
Concurrent Eye Drops	Other topical eye drops must be instilled at least five minutes apart from Ксалаком to prevent wash-out of the solution.
Contact Lenses	Soft contact lenses must be removed prior to application and may be reinserted 15 minutes after the drops are administered.
Systemic Absorption	Nasolacrimal occlusion (pressing on the tear duct) or eyelid closure for two minutes immediately after instillation is recommended to minimize absorption into the body.
Missed Dose	If a scheduled dose is missed, treatment should continue with the next planned dose at the usual time; an extra drop must not be taken.

The dosage of one drop once daily applies to adults, including the elderly. However, the safety and effectiveness in children and adolescents have not been established; therefore, its use is not recommended in this population.

These instructions define a long-term, once-daily regimen designed for consistent, controlled administration.

Research evidence / Overview of studies for Ксалаком

Evidence for use in Primary Open-Angle Glaucoma

Research into the use of the latanoprost/timolol combination for Primary Open-Angle Glaucoma (POAG) has primarily consisted of short-to-medium term Randomized Controlled Trials (RCTs). These studies were used to compare the fixed-dose combination eye drop against using the individual active components (latanoprost or timolol) on their own, as well as against certain other existing fixed-dose combination treatments. Researchers focused on adult patients, including those who had recently been diagnosed and those whose eye pressure met the study criteria for inadequate response to a single glaucoma agent.

The main measure monitored in these studies was the Intraocular Pressure (IOP), a primary biomarker. Trials monitored this pressure at various times of the day to examine patterns observed in the studies over a 24-hour period. Studies monitored the level of pressure measured before and after treatment to examine the difference in pressure measurements. Regulatory assessments described the frequency with which pre-defined target IOP levels were measured in the studied population during the trials.

Evidence for use in Ocular Hypertension

Research has studied the combination in patients with Ocular Hypertension (OHT), a condition where eye pressure is elevated but without visible damage to the optic nerve. Short-term RCTs were used to monitor the core outcome: the change in IOP from the starting level. Studies explored temporary physiological imbalance and reported that the combination was observed in some studies during the assessment of pressure levels. Follow-up durations were limited in the primary efficacy studies, meaning that long-term effects are not fully established and more data are still emerging, particularly for this specific condition.

Long-Term Studies and Durability of Follow-up

To understand the durability of the measured pressure changes, researchers conducted long-term observational studies that tracked patients over periods of two years and sometimes up to five years. These studies focused on the durability of IOP measurements and were used in observational settings evaluating daily-life functioning. The research also helps contextualize how patients reported their experience with the fixed combination, as it was applied in studies examining patient-reported experiences related to adherence.

Key Limitations and Areas of Uncertainty

The research landscape has several defined limitations. One of the primary limitations is that the follow-up durations were limited in many of the key comparative RCTs. Evidence highlights what is known—that is, the observation of the IOP biomarker—and what is still uncertain, namely the long-term observations regarding visual function stability (functional measures) across the entire population. Comparative evidence is lacking for certain newer fixed-dose combinations. This research provides context but not individual predictions.

Key Studies & References Fixed Combination of Latanoprost and Timolol vs Individual Components for Primary Open-Angle Glaucoma or Ocular Hypertension (Pivotal RCT Data)

Common questions about Ксалаком (FAQ)

Q: How quickly should I feel the effect of Ксалаком after starting treatment?

A: According to official regulatory documents, the initial reduction of elevated intraocular pressure (IOP) typically begins approximately three to four hours after the administration of the dose. This is the approximate timeframe when the pressure-lowering action begins.

Q: What is the typical timeframe to see the maximum pressure-lowering effect of Ксалаком?

A: The maximum or peak pressure-lowering effect of the medicine is generally reached approximately eight to twelve hours after the single daily dose has been administered. The treatment is designed for sustained, controlled pressure reduction.

Q: Is it necessary to press on the tear duct after using Ксалаком?

A: Occluding the nasolacrimal duct (pressing gently on the inner corner of the eye next to the nose) or closing the eyelid for two minutes is recommended in the official administration guidelines. This procedure is recommended to help minimize the medicine’s absorption into the body.

Q: Can I use expired Ксалаком if it's only a few days past the date?

A: Official guidance requires the medicine to be discarded four weeks (28 days) after first opening the bottle. Regulatory instructions require the medicine to be discarded after the in-use stability period or expiration date.

Q: Is Ксалаком ever prescribed for ocular hypertension without diagnosed glaucoma?

A: Yes, regulatory documentation indicates its use for the reduction of elevated intraocular pressure (IOP) in patients with ocular hypertension (high eye pressure without optic nerve damage), as well as those with open-angle glaucoma.

Q: Does Ксалаком treat all types of glaucoma?

A: The medicine is indicated for managing pressure in open-angle glaucoma and ocular hypertension. Official documentation notes that it should be used with caution in acute attacks of closed-angle glaucoma until more clinical experience is available.

Q: Is Ксалаком used for anything other than high eye pressure?

A: The sole regulated indication for this medicine, as stated in official product information, is the reduction of elevated intraocular pressure (IOP) associated with ocular hypertension and open-angle glaucoma.

Q: Can Ксалаком change my eye color over time?

A: One of the components, Latanoprost, may gradually increase the amount of brown pigment in the iris. This change occurs slowly, is seen most often in people with mixed-color irides (e.g., blue-brown, green-brown), and official sources indicate the color change may be permanent; this should be monitored by a specialist.

Q: Is it safe to drive after putting in Ксалаком drops?

A: The medicine may cause temporary effects such as blurred vision when first administered. Official guidance states that if temporary blurred vision or other visual disturbances occur, activities like driving or operating machinery should be avoided until vision is clear.

Q: Why do doctors prescribe a combination drop like Ксалаком instead of two separate drops?

A: Clinical studies have shown that fixed-dose combination products can provide a greater reduction in intraocular pressure (IOP) than either active medicine used alone. The combination may also offer a simplified regimen compared to using two separate medicines.

Q: Does the efficacy of Ксалаком decrease over several years of use?

A: According to studies reviewed by regulatory bodies, the Latanoprost component has shown a stable long-term IOP-lowering effect in continuation trials lasting one to two years. No sign of diminishing efficacy was observed during prolonged treatment periods in these studies.

Q: Can Ксалаком affect the growth of eyelashes?

A: Yes, regulatory documents list changes in eyelashes as a possible side effect. This may include a gradual increase in the length, thickness, darkness (pigmentation), and number of lashes or hairs in the treated eye. These changes are typically reversible once treatment is stopped.

Q: What are the signs that Ксалаком is working effectively?

A: The primary clinical measure used to determine effectiveness is the reduction of Intraocular Pressure (IOP). The reduction is a clinical measurement, and effectiveness is monitored by your healthcare professional during routine check-ups.

Q: Is it normal to notice a headache after starting Ксалаком?

A: Headache is listed in the official product information as an uncommon side effect, meaning it may occur in less than 1 in 100 people. If this or any other effect is concerning or persistent, consulting a healthcare professional is recommended.

Q: Can Ксалаком be used in only one eye if the other eye has normal pressure?

A: Dosing instructions state to apply the drops to the affected eye(s). If only one eye requires treatment, the regulatory documentation advises that a difference in iris color (heterochromia) between the two eyes may result, which may be permanent.

Q: What research supports the use of Ксалаком as a first-line treatment?

A: Clinical evidence includes controlled studies that have compared the fixed-dose combination against its individual components and other combination products. This research supports its use for pressure reduction in the indicated populations.

Q: Is it common for one eye to have more side effects from Ксалаком than the other?

A: Regulatory information specifically addresses the long-term side effect of pigmentation. It advises that if only one eye is treated, a permanent difference in color (heterochromia) may result between the two eyes, highlighting that effects can be confined to the treated eye.

Q: Why do doctors often start with a low dose or once-daily application for Ксалаком?

A: The recommended application schedule is once daily. Regulatory information notes that using the medicine more often than the recommended single daily drop may actually reduce the intended effect of the medicine.

Q: What's the difference between eye irritation and an allergic reaction to Ксалаком?

A: Ocular irritation (such as stinging, burning, or eye pain) is listed as a common documented side effect in the safety profile. An allergic reaction (hypersensitivity) is a more serious adverse event and is listed as a contraindication for using the medicine.

Q: Do I need regular check-ups while using Ксалаком?

A: Yes. Official patient information emphasizes that patients using this medicine should be examined regularly. This is necessary for a healthcare professional to monitor the Intraocular Pressure (IOP) and to check for any gradual changes in iris pigmentation.

Q: Does Ксалаком interact with antidepressants or anxiety medications?

A: Due to the medicine containing a beta-blocker component, official information notes that there is a potential for additive effects when taken with other medications that affect heart rate or blood pressure. A healthcare professional should review all concomitant medications for potential additive effects.

How to Store and Dispose of Ксалаком?

The official requirements for storing and disposing of Ксалаком (latanoprost/timolol) ophthalmic solution are strictly defined in regulatory documents to ensure product stability and safety.

Condition	Regulatory Requirement
Unopened Storage Temperature	Store in a refrigerator (2°C to 8°C).
In-Use Storage Temperature	Do not store the opened bottle above 25°C.
In-Use Stability Period	Discard the medicine 4 weeks (28 days) after first opening.
Light Protection	Keep the bottle in its outer carton to protect the solution from light.
Child Safety	Keep out of the sight and reach of children.
Disposal Instructions	Dispose of any unused product or waste material in accordance with local regulatory requirements; do not discard in household waste or wastewater.

This medicine must be protected from light and maintained within the specified temperature ranges before and after opening. The final product disposal must strictly adhere to established pharmaceutical waste procedures.